Amplia Therapeutics Ltd: Proposed issue of securities - ATX
Amplia Therapeutics Ltd: Application for quotation of securities - ATX
Amplia Therapeutics Ltd: Bioshares Conference Presentation
Amplia Therapeutics Ltd: First 26 Patients recruited in Phase 2A ACCENT Trial
Amplia Therapeutics Ltd: Annual General Meeting to be held Friday 23 August 2024
Amplia Therapeutics Ltd: Notification of cessation of securities - ATX
Amplia Therapeutics Ltd: Change of Director's Interest Notice - Dr Robert Peach
Amplia Therapeutics Ltd: Presentation and Webinar
Amplia Therapeutics Ltd: Amplia Establishes World Class Clinical Advisory Board
Amplia Therapeutics Ltd: Appendix 4G - Key to Corporate Governance Disclosures
Amplia Therapeutics Ltd: 2024 Corporate Governance Statement
Amplia Therapeutics Ltd: Preliminary Final Report and Annual Report YE 31 March 2024
Amplia Therapeutics Ltd: ASCO Conference Abstract
Amplia Therapeutics Ltd: Change of Director's Interest Notice - Dr Robert Peach
Amplia Therapeutics Ltd: Change of Director's Interest Notice - Jane Bell
Amplia Therapeutics Ltd: Change of Director's Interest Notice - Chris Burns
Amplia Therapeutics Ltd: Becoming a substantial holder from SOL
Amplia Therapeutics Ltd: Notification regarding unquoted securities - ATX
Amplia Therapeutics Ltd: Change in substantial holding
Amplia Therapeutics Ltd: Becoming a substantial holder from PCG
No Data